Recombinetics announced the development of the first-of-their-kind gene-edited swine models for Neurofibromatosis Type 1 (NF1). Partially funded by the Children’s Tumor Foundation, and in collaboration with the University of Minnesota, these models are for use in preclinical safety and efficacy testing of therapeutics for this debilitating genetic disease affecting 1 [...]
Recombinetics received a $100,000 grant from Regenerative Medicine Minnesota to advance development of an inducible immunodeficient swine to help fill a significant unmet need in biomedicine. The Company appreciates the legislature's dedication to supporting innovation by the regenerative medicine industry in the state of Minnesota.
We couldn't be prouder of our co-founder, Dr. Perry Hackett, who was recognized by his research peers at University of Minnesota's Inventor Recognition Event in the "Impact" category. This award is given to the "researcher whose innovation has most positively and most broadly impacted quality of life. The innovation's impact [...]
